A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
A phase 1/2 trial of DJI136 in small-cell lung cancer, run by Novartis Pharmaceuticals, now recruiting.
Overview
A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy is a phase 1/2 interventional study registered as NCT07564401 by Novartis Pharmaceuticals, with 80 participants planned, started 2026-06-16 and due to reach its primary completion in 2031-03-03. Interventions recorded: DJI136. Conditions listed: Extensive-stage Small Cell Lung Cancer (ES-SCLC). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
Shares Novartis, Small-cell lung cancer.
- TrialA Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
Shares Novartis, Small-cell lung cancer.
- TrialPlatform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Shares Novartis, Small-cell lung cancer.
- CompanyMariana Oncology
Shares Novartis, Small-cell lung cancer.
- TrialRollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other
Shares Novartis, Small-cell lung cancer.
- TargetDLL3
Shares DJI136, Small-cell lung cancer.